() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Invictus MD

Invictus Withdraws Plans for NASDAQ Listing and Related Share Consolidation

May 15, 2019 (GLOBE NEWSWIRE) -- Vancouver, BC, May 15, 2019 – INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) announced today that the Company is withdrawing plans to list the Company’s common shares (the “Shares”) on NASDAQ Stock Market LLC (“NASDAQ”), as well as plans for the share consolidation that would have been required to meet NASDAQ’s minimum share price listing threshold.
Read more

AB LABS AWARDED SALES LICENSE

March 22, 2019 (GLOBE NEWSWIRE) -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that the Company’s licensed producer AB Labs Inc. (“AB Labs") has received a medical sales and processing license from Health Canada effective March 16, 2019, pursuant to the Cannabis Act and Cannabis Regulations (“CACR”).
Read more

INVICTUS PROVIDES PROGRESS UPDATE ON LICENSED PRODUCER EXPANSION

March 04, 2019 (GLOBE NEWSWIRE) -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to provide an update on production and expansion plans at its Licensed Producers: Acreage Pharms Ltd. (“Acreage Pharms”), AB Laboratories Inc. (“AB Labs”) and 0989561 B.C. Ltd.
Read more

Invictus Announces $20 Million Equity Financing

VANCOUVER, British Columbia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announces that it has entered into an agreement with PI Financial Corp. and GMP Securities L.P. as co-lead underwriters on behalf of a syndicate of underwriters (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis pursuant to a short form prospectus, 10,000,000 units (the "Units") of the Company at a price of C$2.00 per Unit (the "Offering Price") for gross proceeds of C$20,000,000 (the "Underwritten Offering"). In connection with the Offering, Eventus Capital Corp. has been appointed as a special advisor to the Company.
Read more
Get $50 in free trades.